Recent Updates
Recently added Catalysts
ONCY Positive Sentiment Score: 70/100

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Key Takeaway: Oncolytics Biotech Inc. will host a conference call and webcast on March 3, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full year financial results for 2022. The company is focused on updating stakeholders on its recent operational developments, especially related to its immunotherapeutic agent pelareorep. This drug is being investigated in various clinical trials aimed at treating several cancer types, providing relevant updates to investors and the market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Oncolytics Biotech is hosting a conference call to discuss positive operational highlights.
  • The company is advancing clinical trials for its immunotherapeutic agent pelareorep.
  • Pelareorep shows promise in enhancing anti-cancer immune responses and synergies with other treatments.

Full Press Release Details

Conference call and webcast to take place on Friday, March 3, 2023, at 8:30 a.m. ET
SAN DIEGO and CALGARY, AB, Feb. 21, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 3, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2022.
Conference Call & Webcast
Date: Friday, March 3, 2023
Dial In – North American Toll-Free: (888) 664-6383
Dial In – International: (416) 764-8650
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 4947-4770
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using replay code: 474-770#.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards registration studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com.
SOURCE Oncolytics Biotech® Inc.

21 %

more press release views with

Frequently Asked Questions

When is the Oncolytics Biotech conference call?

The conference call is scheduled for March 3, 2023, at 8:30 a.m. ET.

How can I join the conference call?

Dial in at 888-664-6383 (North America) or 416-764-8650 (International).

Where can I find the webcast of the call?

The webcast will be available on Oncolytics' Investor Relations page.

What is pelareorep used for?

Pelareorep is used to induce immune responses against various cancers.

Is pelareorep combined with other treatments?

Yes, it shows synergies with immune checkpoint inhibitors and other therapies.

Last updated: Feb 21, 2023